SANDOZ CEFTRIAXONE POWDER FOR SOLUTION

País: Canadà

Idioma: anglès

Font: Health Canada

Compra'l ara

Fitxa tècnica Fitxa tècnica (SPC)
28-01-2010

ingredients actius:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

Disponible des:

SANDOZ CANADA INCORPORATED

Codi ATC:

J01DD04

Designació comuna internacional (DCI):

CEFTRIAXONE

Dosis:

2G

formulario farmacéutico:

POWDER FOR SOLUTION

Composición:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 2G

Vía de administración:

INTRAMUSCULAR

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

THIRD GENERATION CEPHALOSPORINS

Resumen del producto:

Active ingredient group (AIG) number: 0117292002; AHFS:

Estat d'Autorització:

CANCELLED PRE MARKET

Data d'autorització:

2018-08-01

Fitxa tècnica

                                _ _
PRODUCT MONOGRAPH
SANDOZ CEFTRIAXONE
Sterile Ceftriaxone for Injection BP
1 G AND 2 G CEFTRIAXONE PER VIAL (INCORPORATED AS CEFTRIAXONE SODIUM)
ANTIBIOTIC
Sandoz Canada Inc.
Date of Revision: January 15, 2010
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
CONTROL # : 133307
_Sandoz Ceftriaxone _
_ Page 2 of 51_
_ _
TABLE OF CONTENTS
HEALTH PROFESSIONAL
INFORMATION.........................................................................
3
ACTION
.....................................................................................................................................
3
INDICATIONS AND CLINICAL
USES...................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS...............................................................................................................................
4
PRECAUTIONS.........................................................................................................................
6
ADVERSE
REACTIONS...........................................................................................................
8
SYMPTOMS AND TREATMENT OF OVERDOSAGE
....................................................... 10
DOSAGE AND
ADMINISTRATION.....................................................................................
10
ADMINISTRATION................................................................................................................
11
PHARMACEUTICAL
INFORMATION.................................................................................
13
DRUG
SUBSTANCE...............................................................................................................
13
DRUG
PRODUCT....................................................................................................................
13
RECONSTITUTION
.......................................................................................
                                
                                Llegiu el document complet
                                
                            

Cerqueu alertes relacionades amb aquest producte